
Fremanezumab was shown to clinically improve headache-related disability outcomes in patients with either chronic or episodic migraines and reported inadequate response to 2 to 4 classes of migraine preventative medications, according to a study presented at the 144th Annual Meeting of the American Neurological Association.




























